肿瘤免疫学：推动基础和临床进展的多学科科学。
Tumor immunology: multidisciplinary science driving basic and clinical advances.
出版信息
Cancer Immunol Res. 2013 Jul;1(1):16-23. doi: 10.1158/2326-6066.CIR-13-0011.
Abstract
The fourth AACR Special Conference "Tumor Immunology: Basic and Clinical Advances" was held in Miami, FL in December 2012. The overall objective of this meeting was to discuss emerging concepts in cancer immunology and immunotherapy. The key findings that emerged from this meeting included: (i) multiple immune checkpoints should be inhibited to increase effective T-cell therapy, (ii) successful adoptive T-cell therapy will rely on obtaining the proper T-cell phenotype, (iii) chimeric antigen receptors have shown promise in treating some B-cell malignancies, and (iv) multiple pathways of inflammation within the tumor microenvironment are immunotherapy targets.
摘要
2012 年 12 月，第四届 AACR 特别会议“肿瘤免疫学：基础与临床进展”在佛罗里达州迈阿密举行。本次会议的总体目标是讨论癌症免疫学和免疫治疗方面的新观念。本次会议提出的主要观点包括：（i）抑制多种免疫检查点以增强有效的 T 细胞治疗效果，（ii）成功的过继性 T 细胞治疗将依赖于获得适当的 T 细胞表型，（iii）嵌合抗原受体在治疗某些 B 细胞恶性肿瘤方面显示出希望，以及（iv）肿瘤微环境中的多条炎症途径是免疫治疗的靶点。
相似文献
1
Tumor immunology: multidisciplinary science driving basic and clinical advances.肿瘤免疫学：推动基础和临床进展的多学科科学。
Cancer Immunol Res. 2013 Jul;1(1):16-23. doi: 10.1158/2326-6066.CIR-13-0011.
2
Tumor immunology: basic and clinical advances.肿瘤免疫学：基础与临床进展。
Cancer Res. 2011 Jul 1;71(13):4338-43. doi: 10.1158/0008-5472.CAN-11-0717. Epub 2011 Jun 28.
3
Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.基于过继性细胞疗法和免疫检查点阻断疗法的实体瘤个性化联合免疫疗法的前景。
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68.
4
The Role of Tumor Microenvironment in Cancer Immunotherapy.肿瘤微环境在癌症免疫治疗中的作用。
Adv Exp Med Biol. 2017;1036:51-64. doi: 10.1007/978-3-319-67577-0_4.
5
Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.嵌合抗原受体 T 细胞疗法治疗癌症：以基础研究为导向的观点。
Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.
6
Translating Science into Survival: Report on the Fifth International Cancer Immunotherapy Conference.将科学转化为生存之道：第五届国际癌症免疫治疗会议报告。
Cancer Immunol Res. 2020 Jan;8(1):3-6. doi: 10.1158/2326-6066.CIR-19-0888.
7
Tumor Immunology and Tumor Evolution: Intertwined Histories.肿瘤免疫学和肿瘤进化：交织的历史。
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
8
Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference.将科学转化为生存之道：第二届国际癌症免疫治疗会议报告。
Cancer Immunol Res. 2016 Dec;4(12):996-1000. doi: 10.1158/2326-6066.CIR-16-0276.
9
Recent advances in cancer immunology and immunology-based anticancer therapies.癌症免疫学和基于免疫学的抗癌疗法的最新进展。
Biomed Pharmacother. 2017 Dec;96:1491-1500. doi: 10.1016/j.biopha.2017.11.126. Epub 2017 Dec 2.
10
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.肿瘤微环境作为效应 T 细胞和免疫疗法的代谢障碍。
Elife. 2020 May 5;9:e55185. doi: 10.7554/eLife.55185.
引用本文的文献
1
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival.软组织肉瘤中肿瘤浸润性T细胞上的LAG-3表达与不良预后相关。
Cancer Biol Med. 2019 May;16(2):331-340. doi: 10.20892/j.issn.2095-3941.2018.0306.
2
Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma.银纳米颗粒的免疫调节特性有助于制定针对小鼠纤维肉瘤的抗癌策略。
Cell Mol Immunol. 2016 Mar;13(2):191-205. doi: 10.1038/cmi.2015.05. Epub 2015 May 4.
3
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.非病毒致癌抗原以及驱动癌症早期发展的炎症信号作为癌症免疫预防的靶点。
Clin Cancer Res. 2015 Apr 1;21(7):1549-57. doi: 10.1158/1078-0432.CCR-14-1186. Epub 2015 Jan 26.
4
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.下一代临床试验：应对肿瘤分子异质性挑战的新策略。
Mol Oncol. 2015 May;9(5):967-96. doi: 10.1016/j.molonc.2014.09.011. Epub 2014 Oct 18.
本文引用的文献
1
Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.利用甲氨蝶呤抗性人二氢叶酸还原酶高效选择基因修饰的人 T 细胞。
Gene Ther. 2013 Aug;20(8):853-60. doi: 10.1038/gt.2012.97. Epub 2013 Jan 10.
2
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.吲哚胺 2,3-双加氧酶（IDO）抑制刺激 mTOR 的色氨酸充足信号：D-1-甲基色氨酸靶向的新型 IDO 效应途径。
Oncoimmunology. 2012 Dec 1;1(9):1460-1468. doi: 10.4161/onci.21716.
3
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.前列腺癌骨转移的预防与治疗进展。RANK/RANKL抑制的作用。
Actas Urol Esp. 2013 May;37(5):292-304. doi: 10.1016/j.acuro.2012.09.001. Epub 2012 Dec 13.
4
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.通过操纵 CD8+T 细胞耐受的多个调节途径产生的白血病持久过继免疫治疗。
Cancer Res. 2013 Jan 15;73(2):605-16. doi: 10.1158/0008-5472.CAN-12-2179. Epub 2012 Nov 27.
5
Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.采用 EBV 核抗原 1 特异性 T 细胞过继转移作为异基因干细胞移植后 EBV 再激活和淋巴增殖性疾病的治疗方法。
J Clin Oncol. 2013 Jan 1;31(1):39-48. doi: 10.1200/JCO.2011.39.8495. Epub 2012 Nov 19.
6
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.临床级制备的慢病毒修饰的 CD19 特异性人 CD8+ 中央记忆 T 细胞的表型和功能特征。
J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.
7
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?分类筛选：哪些 T 细胞亚群介导了高效的过继免疫治疗？
J Immunother. 2012 Nov-Dec;35(9):651-60. doi: 10.1097/CJI.0b013e31827806e6.
8
Paths to stemness: building the ultimate antitumour T cell.通向干细胞之路：构建终极抗肿瘤 T 细胞。
Nat Rev Cancer. 2012 Oct;12(10):671-84. doi: 10.1038/nrc3322. Epub 2012 Sep 21.
9
IDO is a nodal pathogenic driver of lung cancer and metastasis development.IDO 是肺癌及转移发展的一个关键性的致瘤驱动因素。
Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19.
10
Th17 cells have stem cell-like features and promote long-term immunity.Th17 细胞具有干细胞样特征，并促进长期免疫。
Oncoimmunology. 2012 Jul 1;1(4):516-519. doi: 10.4161/onci.19440.
Zotero 插件